Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs DreamHug Medical

Two GLP-1 desks, one scoreboard. We put Trimi and DreamHug Medical head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 365 · Grade C

DreamHug Medical

Visit DreamHug Medical Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 57 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make DreamHug Medical a bad call — it's best for readers who want money-back-guaranteed semaglutide eval with a public florida address. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
48
Supply Reliability
89
54
Transparency
91
48
Access Breadth
89
90
Clinical Oversight
88
60
Track Record
84
50
TrimiBrief Score 89 · 57DreamHug Medical

Price, coverage & the tracker

TrimiDreamHug Medical
Brief Score89/100 (B+)57/100 (C)
Semaglutide$196/moFrom $188/mo (starting dose, compounded)
Tirzepatide$296/moFrom $238/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

DreamHug Medical: New to the tracker on 1 August 2026. The published line reads From $188/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.